Guillermo Ramil López
YOU?
Author Swipe
View article: Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group
Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group Open
Background The treatment landscape of acute myeloid leukemia (AML) is rapidly evolving due to advances in novel targeted agents, lower-intensity treatments, and allogeneic stem cell transplantation. Simultaneously, technologic advances are…
View article: Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers
Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers Open
Introduction After an allogeneic hematopoietic stem cell transplantation (allo-HSCT), a wide range of complications may occur. One of the less common, yet clinically significant, is the development of a donor-cell derived hematologic neopl…
View article: Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations Open
View article: Measurable Residual Disease in <i>UBTF</i>‐TD Adult Acute Myeloid Leukemia
Measurable Residual Disease in <i>UBTF</i>‐TD Adult Acute Myeloid Leukemia Open
View article: Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia Open
Not available.
View article: Be aware of the X: <i>BCOR</i> mutations in myeloid neoplasms
Be aware of the X: <i>BCOR</i> mutations in myeloid neoplasms Open
Not available.
View article: PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing Open